Abstracts tagged "DMARDs"

Abstract Number: 389 • 2017 ACR/ARHP Annual Meeting
S-110483 a New Potent EP4 Receptor Antagonist with Immunomodulatory and Analgesic Activities
Takashi Maeda¹, Toshitaka Ochiai², Toshie Nagayasu-Tanaka¹, Yuta Morisaki¹, Haruka Takizawa¹, Seiji Ishihara¹, Shigeo Kurokawa¹, Kiyoharu Ukai¹ and Masahiro Suda¹, ¹Pharmacology Department, Kaken Pharmaceutical Co., LTD, Kyoto, Japan, ²Kaken Pharmaceutical Co., LTD, Kyoto, Japan
Background/Purpose: Prostaglandin (PG) E2 is known to enhance the expansion of T helper 17 (Th17) cell population via EP4 receptor (EP4) in the early phase…
Abstract Number: 1159 • 2017 ACR/ARHP Annual Meeting
National Recommendations on the Use of Immunomodulatory Drugs in Patients with NON-Infectious NON-Malignant Anterior Uveitis
Gerard Espinosa¹, Santiago Muñoz², Jose M Ruiz de Morales³, Jose M Herreras⁴ and Miguel Cordero-Coma⁵, ¹Autoimmune Diseases Department. Hospital Clínic de Barcelona, Barcelona, Spain, ²Rheumatology, Hospital Infanta Sofia, Madrid, Spain, ³Complejo Asistencial Universitario de León, León, Spain, ⁴Ophthalmology, Hospital Universitario, IOBA, Valladolid, Spain, ⁵Ophthalmology, Hospital de León. Spain, León, Spain
Background/Purpose: Anterior uveitis (AU) is the most common pattern of uveitis, that migh lead to important ocular complications including blindness. Immunomodulatory drugs have been used…
Abstract Number: 2404 • 2017 ACR/ARHP Annual Meeting
Use of Dmards after the Diagnosis of Cancers in Patients with RA
Young Bin Joo, Yune-Jung Park, Ki-Jo Kim and Kyung-Su Park, Internal Medicine, St. Vincent's Hospital, The Catholic University of Korea, Suwon, Korea, Republic of (South)
Background/Purpose: Although there are many studies about the association of disease-modifying anti-rheumatic drugs (DMARDs) with cancers in patients with rheumatoid arthritis (RA), there are few…
Abstract Number: 390 • 2017 ACR/ARHP Annual Meeting
S-110483, a Novel and Selective EP4 Receptor Antagonist with Anti-Bone Destruction Activities
Toshitaka Ochiai¹, Takashi Maeda², Toshie Nagayasu-Tanaka², Jun Anzai¹, Daiki Kato¹, Yuta Morisaki², Kiyoharu Ukai² and Masahiro Suda², ¹Kaken Pharmaceutical Co., LTD, Kyoto, Japan, ²Pharmacology Department, Kaken Pharmaceutical Co., LTD, Kyoto, Japan
Background/Purpose: S-110483 is our novel potent and selective EP4 receptor (EP4) antagonist. In addition to the well-known fact that EP4 antagonists have anti-inflammatory effects, it…
Abstract Number: 1311 • 2017 ACR/ARHP Annual Meeting
Pregnancy Outcome in Chinese Women with Rheumatic Disease Treated By Leflunomide (LEF)
Yan Zhao¹, lingxun shen², zongwen shuai³, Hengli Zhao⁴, Weinan Lai⁵, Xiaoling Lai⁶, Shaoying Zhang⁷, Xuequn Wang⁸, Shaoxian Hu⁹, Wenli Chen¹⁰, Wei Ji¹¹, Hua Wei¹², Qi Zhang¹³, Lixia Pang¹⁴, huaxiang Liu¹⁵, Qiang Shu¹⁵, Jun-li Zhang¹⁶, Yating Zhou¹⁷, Qiong Jiang¹⁸, Huaxiang Wu¹⁹, Jing Xue¹⁹, Ganping Bai²⁰, Li Zhang²¹ and Fei Xiao²¹, ¹Rheumatology, Peking Union Medical College Hospital, Beijing, China, ²Wuhan Union Hospital, wuhan, China, ³The First Affiliated Hospital of Anhui University, Hefei, China, ⁴Yantai Hospital of Traditional medicine University, Yantai, China, ⁵Nanfang Hospital, Guangzhou, China, ⁶Guangxi Hospital of Traditional Chinese Medicine, Nanning, China, ⁷Yiling Hospital, Yiling, China, ⁸The First Affiliated Hospital of Xinyang, Xinyang, China, ⁹Tongji hospital, wuhan, China, ¹⁰Wuhan Central Hospital, wuhan, China, ¹¹Jiangsu Province Hospital of TCM, Nanjing, China, ¹²Subei People's Hospital, Yangzhou, China, ¹³Dongying central hospital, Dongying, China, ¹⁴Dongying Hospital, Dongying, China, ¹⁵Qilu hospital of Shandong University, Jinan, China, ¹⁶Rheumatology, The Fifth Hospital of Xi’an City, Xi’an, China, ¹⁷Xian No5 Hospital, Shandong, China, ¹⁸Taizhou Hospital, Taizhou, China, ¹⁹The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China, ²⁰Chongqing Southwest Hospital, Chongqing, China, ²¹Gothic Internet Technology Corporation, Shanghai, China
Background/Purpose: LEF is a first line DMARD. Due to the teratogenic effects in offspring of rats in preclinical study, the patients who plan to get…
Abstract Number: 2469 • 2017 ACR/ARHP Annual Meeting
Median Time to Lda Is Shorter in Tocilizumab Combination Therapy with Csdmards As Compared to Monotherapy in Patients with Active Rheumatoid Arthritis and Inadequate Responses to Csdmards and/or TNF Inhibitors: Sub-Analysis of the Swiss and Austrian Patients from the ACT-SURE Study
Ruediger Mueller¹, Winfried Graninger², Páris Sidiropoulos³, Christoph Goger⁴ and Johannes von Kempis⁵, ¹Rheumatology, MD, St. Gallen, Switzerland, ²Rheumatology and Immunology, Medical University of Graz, Graz, Austria, ³F. Hoffmann-La Roche Ltd, South San Francisco, CA, ⁴Roche Austria GmbH, Vienna, Austria, ⁵Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland
Background/Purpose: To analyze efficacy and safety of tocilizumab in patients with rheumatoid arthritis (RA) and an inadequate response to conventional synthetic disease modifying anti-rheumatic drugs…
Abstract Number: 408 • 2017 ACR/ARHP Annual Meeting
CR6086 Is Highly Effective and Improves Methotrexate Effect in a Mouse Model of Rheumatoid Arthritis
Gianfranco Caselli¹, Flora Ferrari¹, Eleonora Comi¹, Marco Perrella¹, Camilla Recordati², Adriana Grotti¹, Rosanna Cavagnoli¹, Marco Lanza¹ and Lucio C. Rovati³, ¹Rottapharm Biotech, Monza, Italy, ²Mouse & Animal Pathology Lab,, Fondazione Filarete, Milano, Italy, Milano, Italy, ³Clinical Research Department, Rottapharm Biotech, Monza, Italy
Background/Purpose: CR6086, a selective EP4 antagonist, dose-dependently improves disease features in rheumatoid arthritis (RA) models in rodents. Indeed, recent studies highlight the role of the…
Abstract Number: 1316 • 2017 ACR/ARHP Annual Meeting
Risk of Preterm Delivery Associated with Perinatal Exposure to Dmards in Women with Inflammatory Arthritis: A Population-Based Cohort Study
Nicole W. Tsao^1,2, Eric C. Sayre², Mohsen Sadatsafavi¹, J. Antonio Avina-Zubieta^2,3, Stephanie Ensworth⁴ and Mary A. De Vera^1,2, ¹Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, ²Arthritis Research Canada, Richmond, BC, Canada, ³Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada, ⁴University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Given the limited data on impacts of perinatal medication use, our objective was to investigate the association between conventional synthetic DMARD (csDMARD) use preconception…
Abstract Number: 2493 • 2017 ACR/ARHP Annual Meeting
Efficacy and Safety of Tofacitinib in Patients with Rheumatoid Arthritis and Inadequate Response or Intolerance to Prior Therapies
John Tesser¹, Ahmet Gül², Ewa Olech³, Kurt Oelke⁴, Tatjana Lukic⁵, Christopher W Murray⁶, Chuanbo Zang⁶ and Liza Takiya⁶, ¹Arizona Arthritis & Rheumatology Associates, Glendale, AZ, ²Istanbul University, Istanbul, Turkey, ³UNLV School of Medicine, Las Vegas, NV, ⁴Rheumatic Disease Center, Glendale, WI, ⁵Pfizer Inc, New York, NY, ⁶Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Patients (pts) with RA generally receive conventional synthetic DMARDS (csDMARDs)…
Abstract Number: 435 • 2017 ACR/ARHP Annual Meeting
Characteristics of Rheumatoid Arthritis Patients Who Have a DMARD Interruption and the Impact of Using a Bridging Medication on Clinical and Patient Reported Outcomes
Christine Iannaccone¹, Michelle Frits², Taysir G. Mahmoud³, Gabriela Maica⁴, Jonathan Coblyn⁵, Michael Weinblatt² and Nancy A. Shadick⁶, ¹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Department of Rheumatology, Allergy, and Immunology, Brigham and Women's Hospital, Boston, MA, ⁵Department of Rheumatology, Brigham & Womens Hospital, Boston, MA, ⁶Rheumatology Immunology & Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: It is common for RA patients to interrupt their DMARD use due to events like infection, surgery, or pregnancy. Many RA patients may need…
Abstract Number: 1425 • 2017 ACR/ARHP Annual Meeting
Treatment Patterns in Patients with Rheumatoid Arthritis Newly Initiated on Biologic and Non-Biologic Therapy Enrolled in a North American Clinical Registry
Philip J Mease¹, Neil Accortt², Mei Liu³, Sabrina Rebello³, Mahdi Gharaibeh² and David Collier², ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Amgen Inc., Thousand Oaks, CA, ³Corrona, LLC, Southborough, MA
Background/Purpose: Many treatment options are currently available to patients with rheumatoid arthritis (RA), including tumor necrosis factor inhibitors (TNFi’s). While combination therapy of TNFi’s or…
Abstract Number: 2523 • 2017 ACR/ARHP Annual Meeting
The Prevalence, Incidence and Associated Factors for Liver Abnormalities in Psoriatic Arthritis: Resutls from a Longitudinal Observational Cohort
Rattapol Pakchotanon¹, Justine (Yang) Ye¹, Richard J. Cook², Vinod Chandran³ and Dafna D Gladman³, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ³Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disease which affects the skin and musculoskeletal system. PsA patients frequently suffer from comorbidities: cardiovascular disease, metabolic…
Abstract Number: 516 • 2017 ACR/ARHP Annual Meeting
Efficacy of Adding Iguratimod Therapy in Rheumatoid Arthritis　Patients Who Had Inadequate Response to Biologic Dmards
Toshiaki Miyamoto, Rheumatology, SEIREI HAMAMATSU GENERAL HOSPITAL, Hamamatsu, Japan
Background/Purpose: Iguratimod (IGU) was approved in June 2012 and recommended by JCR guideline 2014 in the treatment of rheumatoid arthritis (RA). Although there have been…
Abstract Number: 1454 • 2017 ACR/ARHP Annual Meeting
Association of Poor Prognostic Factors with Medication Persistence Among Adult RA Patients within a Community of Rheumatology Clinics
Damemarie Paul¹, Laura McDonald², Aarti Rao³, Ruthwik Anupindi⁴ and Keith Knapp^5,6, ¹HEOR, Bristol Myers Squibb, Lawrence Township, NJ, ²CORDS, Bristol Myers Squibb, Uxbridge, United Kingdom, ³Analytics, Mu-Sigma, Bengaluru, India, ⁴Analytics, Mu-Sigma, Lawrence Township, NJ, ⁵Arthritis Northwest PLLC., Spokane, WA, ⁶Discus Analytics LLC., Spokane, WA
Background/Purpose: A fixed treatment paradigm often exists for Rheumatoid Arthritis(RA) patient(pts)1. However, RA is a heterogeneous disease and differences in pts’ serostatus affect disease progression.…
Abstract Number: 2744 • 2017 ACR/ARHP Annual Meeting
Long-Term Remission in Severe Behcet’s Disease Following Withdrawal of Successful Anti-TNF Treatment
Petros P Sfikakis¹, Aikaterini Arida¹, Stylianos Panopoulos², Kalliopi Fragkiadaki², George Pentazos³, Katerina Laskari³, Maria Tektonidou¹ and Nikos Markomichelakis², ¹First Department of Propaedeutic and Internal Medicine and Joint Rheumatology Program, National and Kapodistrian University of Athens Medical School, athens, Greece, ²First Department of Propaedeutic and Internal Medicine and Joint Rheumatology Program, National and Kapodistrian University of Athens Medical School, Athens, Greece, ³Rheumatology Unit, 1st Dept. of Propaedeutic Internal Medicine, Joined Academic Rheumatology Program, Athens University Medical School, Athens, Greece
Background/Purpose: Anti-TNF treatment has been shown to be effective in inducing complete remission in many Behcet’s disease (BD) patients with eye, large vessel, intestine and…

« Previous Page
1
…
6
7
8
9
10
…
24
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].